Oncology Devices Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The oncology devices market is poised for significant expansion in the coming years, driven by technological advancements and growing healthcare demands. As cancer treatment becomes increasingly personalized and precise, this sector is experiencing rapid innovation and investment, positioning it for robust growth through 2030. Let's delve into the market's expected size, key players, emerging trends, and segmentation details.

Projected Market Value and Growth Trajectory of the Oncology Devices Market
The oncology devices market is anticipated to witness remarkable growth, reaching a valuation of $397.27 billion by 2030. This corresponds to a compound annual growth rate (CAGR) of 17.3% over the forecast period. Factors contributing to this surge include the rising adoption of personalized cancer treatment technologies, increased investment in oncology infrastructure, growth in outpatient cancer care centers, and the expanding use of AI-powered diagnostic tools. Additionally, there is a growing emphasis on precision oncology solutions, which are shaping the market's upward trajectory. Key trends expected to influence the industry include wider implementation of advanced cancer diagnostic devices, greater use of image-guided oncology treatments, integration of minimally invasive therapy tools, development of precision radiation therapy equipment, and enhanced strategies for early cancer detection.

Download a free sample of the Oncology Devices market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3373&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Leading Players Driving the Oncology Devices Market Forward
Several prominent companies dominate the oncology devices landscape, including Eckert & Ziegler BEBIG GmbH, Oncura Inc., GE Healthcare, Medtronic plc, Varian Medical Systems Inc., Elekta AB, Theragenics Corporation, Accuray Incorporated, Roche Diagnostics, IBA Group, Biogenex Laboratories, Becton dic*kinson and Company, Siemens Healthineers, Philips Healthcare, Hologic Inc., IBA AG, ViewRay Inc., Canon Medical Systems Corporation, Brainlab, PerkinElmer, RaySearch Laboratories, Mevion Medical Systems, Vision RT, IsoRay, RefleXion Medical, Alpha Tau Medical, Nanobiotix, Mirada Medical Ltd., and Navidea Biopharmaceuticals Inc. These organizations are at the forefront of innovation and market development in oncology technology.

Significant Strategic Acquisition Highlighting Market Expansion
In March 2024, Halma PLC, a UK-based company specializing in life-saving technology, expanded its oncology portfolio by acquiring Rovers Medical Devices B.V. for $93.5 million. This acquisition is aimed at strengthening Halma's capabilities in women's health and cancer diagnostics. Rovers Medical Devices B.V., headquartered in the Netherlands, is known for designing and manufacturing medical devices focused on cancer screening. This move underlines Halma's commitment to enhancing its market presence in critical oncology sectors.

View the full Oncology Devices market report:
https://www.thebusinessresearchcompany.com/report/oncology-devices-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR

Emerging Trends Shaping the Future of the Oncology Devices Market
Industry leaders are prioritizing the development of highly precise, patient-focused oncology devices to boost treatment effectiveness, safety, and operational efficiency. Innovations are increasingly centered on minimally invasive technologies, superior visualization tools, and real-time therapy adjustments. For example, in April 2025, ZEISS, a Germany-based medical technology firm, received FDA 510(k) clearance for its INTRABEAM 700 system. This next-generation robotic-assisted intraoperative radiotherapy (IORT) platform offers targeted radiation delivery specifically for neuro-oncology and breast cancer surgeries. The system enhances precision and ergonomics, and integrates smoothly into surgical workflows, allowing clinicians to administer localized radiation during surgery while protecting surrounding healthy tissues. By combining advanced imaging, robotics, and treatment planning, the INTRABEAM 700 exemplifies the sector's shift toward technologically sophisticated and patient-centric cancer care.

Detailed Breakdown of the Oncology Devices Market Segmentation
The oncology devices market is systematically segmented into several categories for clearer analysis:
1) Device Type: This includes Brachytherapy Devices and Endoscopic Devices.
2) Therapy Type: Encompassing Chemotherapy, Hormone Therapy, Biotherapy/Immunotherapy, and Radiation Therapy.
3) End User: Covering Hospitals, Cancer Research Institutes, and other healthcare providers.

Further subsegments under Brachytherapy Devices feature Afterloaders (both High-Dose Rate and Low-Dose Rate), Applicators, Seeds, and Accessories. The Endoscopic Devices category includes Flexible, Rigid, and Capsule Endoscopes, Endoscopic Ultrasound Systems, and related Accessories. This segmentation provides a comprehensive framework to understand the various components driving the oncology devices market.

What's included in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.